Investment Analysts’ Recent Ratings Updates for Taysha Gene Therapies (TSHA)

A number of firms have modified their ratings and price targets on shares of Taysha Gene Therapies (NASDAQ: TSHA) recently:

• 1/6/2026 – Taysha Gene Therapies had its “strong-buy” rating reaffirmed by analysts at Raymond James Financial, Inc.. They now have a $13.00 price target on the stock.
• 1/6/2026 – Taysha Gene Therapies had its “buy” rating reaffirmed by analysts at Chardan Capital. They now have a $12.00 price target on the stock.
• 1/5/2026 – Taysha Gene Therapies had its price target raised by analysts at Wells Fargo & Company from $8.00 to $11.00. They now have an “overweight” rating on the stock.
• 1/3/2026 – Taysha Gene Therapies was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 12/29/2025 – Taysha Gene Therapies had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/22/2025 – Taysha Gene Therapies had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/15/2025 – Taysha Gene Therapies had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/13/2025 – Taysha Gene Therapies was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 12/8/2025 – Taysha Gene Therapies had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/4/2025 – Taysha Gene Therapies was given a new $11.00 price target on by analysts at The Goldman Sachs Group, Inc..
• 12/4/2025 – Taysha Gene Therapies was given a new $11.00 price target on by analysts at UBS Group AG.
• 12/4/2025 – Taysha Gene Therapies was upgraded by analysts at The Goldman Sachs Group, Inc. to a “buy” rating.
• 12/1/2025 – Taysha Gene Therapies had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/25/2025 – Taysha Gene Therapies had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.

Insider Activity

In other Taysha Gene Therapies news, insider Sukumar Nagendran sold 200,000 shares of the business’s stock in a transaction on Monday, January 12th. The stock was sold at an average price of $4.71, for a total value of $942,000.00. Following the sale, the insider directly owned 1,006,439 shares in the company, valued at $4,740,327.69. The trade was a 16.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders sold 570,172 shares of company stock valued at $2,637,906 in the last 90 days. Insiders own 3.78% of the company’s stock.

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.